Atopica Logo
Imaverol logo in red on white.
Itrafungol logo on white
Osurnia logo on white.
Surolan logo on white.
Deramaxx logo on white.
Onsior logo and tag line on white
Clomicalm logo on white.
Fortekor logo on white.
Percorten-V logo on white.
Comfortis logo on white
Trifexis logo on white.
Sentinal logo on white.
Interceptor Flavor Tabs Logo
Milbemax logo ond tag line on white.
Lapatol logo on white
Capstar logo on white
Atopica for Cats Logo
Program image on white
Surosolve logo on white.

Atopica Logo

Target the underlying problems associated with canine atopic dermatitis rather than just chasing the symptoms. Get long lasting control with Atopica, the proven long-term solution

Atopica® Capsules

Atopica is an oral form of cyclosporine, a non-steroidal immune modulating agent that has been helping to provide safe and effective control of the clinical signs of atopic dermatitis in dogs for over 10 years.

By concentrating in the skin where it’s needed most1 it targets the requirement for routine monitoring of therapeutic blood levels. Atopica® also specifically targeting the immune cells involved in the allergic response, which helps to reduce itch and skin lesions while minimizing long term side effects.

Get long lasting control with Atopica®, the proven long-term solution

With continued use and as clinical signs improve; the dosing frequency of Atopica® can be lowered, reducing the need to medicate daily. Because Atopica® can help improve the overall health of the skin, this can reduce the susceptibility to secondary infections and also the costs and hassles of repeated visits for these additional issues2

Important safety information

The label contains complete use information, including cautions, and warnings. Always read, understand and follow the label, and use directions.

Gastrointestinal upsets are the most common adverse effects, but these are typically transient, occur in the first month of treatment, and are likely related to the excipients in the oral micro-emulsified formulation. Overall, side effects related to Atopica® are usually mild, do not require treatment, and rarely require discontinuation3

For full safety information, please consult product label. Pet owners should contact their veterinarians immediately if a suspected adverse drug event is noted.

For veterinarians: To report suspected adverse drug events or for technical assistance, please contact Elanco Canada Limited at 1-800-265-5475.

Directions for Use

The initial target daily dose of Atopica® is 5 mg/kg/day (range of 3.3 - 6.7 mg/kg/day) given as a single daily dose for 30 days. Following this induction treatment period, the dose of Atopica® may be tapered by decreasing the frequency of dosing from daily to every other day, and then to once every 3 to 4 days until a minimum frequency is reached which will maintain the desired therapeutic effect.


  1. Steffan et. al. Cyclosporine concentration in the skin following oral administration, in Proceedings. 18th Ann ESVD-ECVD Cong 2002; 222
  2. Steffan et al. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol. 2003 Feb; 14(1):11-22
  3. Nuttall T., Reece D., Roberts E. (2014) Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Veterinary Record 174, (suppl 2), 3–11